Improving communications in clinical oncology: the EuroCODE project. The EuroCODE Steering Committee. by Fayers, P. M. et al.
Br. J. Cancer (1992), 66, 607 609 © Macmillan Press Ltd., 1992
GUEST EDITORIAL
Improving communications in clinical oncology: the EuroCODE project
P.M. Fayers, D. Machin, J. Mossman on behalf of The EuroCODE steering committee*
Each year there are approximately 750,000 deaths and more
than one million newly diagnosed cases of cancer in the
European Community (Moller-Jensen et al., 1990).
Although progress has been made in recent years in the
development of effective cancer therapies, at least for some
tumour types, this progress has not always translated into
changes in clinical practice. This is not only a European
problem as a report of the USA Government Accounting
Office (1988) indicated that many patients are not receiving
state-of-the-art therapy, in particular 37% of premenopausal
women with stage II, node positive breast cancer did not
receive adjuvant therapy although it is known to bring
benefit.
There are several important reasons for this. One is that
the results are often communicated through articles in a
diverse assortment of scientific journals, with consequent
publication delays and more importantly perhaps a restricted
readership. A second reason is that the evidence so published
is not sufficiently compelling to convince clinicians of the
value of the new therapy compared to the standard therapy
with which they are familiar. It may be that the result
requires confirmation in a large collaborative trial before this
uncertainty is removed. A third reason, associated with the
second, is that the effect of the new therapy, although estab-
lished beyond reasonable doubt, may not appear very strik-
ing to the clinician in the context of an individual patient
about to be treated. Thus a proved 5% advantage of a new
therapy does not offer a great deal to an individual patient.
Although the public health impact of a small but important
difference may be considerable and may save many lives per
year, it may not be appreciated by the attending physician or
an individual patient.
Modern computer technology can be exploited to assist
both in the rapid dissemination of results and in the organis-
ation of large collaborative trials run on a regional, national
or international basis. The need for, and appropriate size of,
such trials has been reviewed by Freedman (1989). To
achieve this the EuroCODE (European Computerized
Oncology Data Exchange) project was recommended by the
European Action Against Cancer and its expert committee. It
was funded after approval by the cancer research working
party of the Fourth Medical and Health Research pro-
gramme of the European Community (EC) and is coor-
dinated through the European Organization for Research
and Treatment of Cancer (EORTC). The project commenced
operation in 1988 (EuroCODE Steering Committee, 1990).
Its purpose is to assist those concerned with cancer treatment
to obtain the most up-to-date and reliable information
available, to facilitate patient entry into collaborative clinical
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trials and to enable rapid exchange of electronic mail
between clinicians and investigators.
Technically, EuroCODE consists of an international net-
work of computers connected to each other by means of
public telephone lines. At present over 300 investigators from
17 European countries use EurCODE on a regular basis, as
do a number of Cancer Trial Offices throughout Europe.
Facilities
Information databases
EuroCODE gives direct access to information databases that
are directly relevant to cancer clinical practice. These encom-
pass lists of on-going clinical trials, dates of oncology-related
conferences, workshops and educational meetings such as
those of the European School of Oncology. In addition it
provides access to the Physician Data Query (PDQ) database
which is supported by the US National Cancer Institute
(NCI).
The PDQ system (Hubbard et al., 1987) includes sum-
maries of current cancer management information of direct
relevance to individual patient care, and is supervised by a
multidisciplinary editorial board of 31 clinical scientists and
an extramural board of 75 scientists. There are 76 state-of-
the-art treatment statements listed, together with 13 support-
ive care statements and 42 standard therapy protocols. This
patient management information is continuously updated as
new information on therapies becomes available. The system
also lists all ongoing national and international, NCI/PDQ-
board approved, trial protocols including, amongst others,
protocols from the Cancer Research Campaign (CRC) and
the Medical Research Council (MRC) for the UK, and from
the EORTC for Europe. Protocol summaries for 1,445 open
trials can currently be examined over EuroCODE; it is plan-
ned also to make available the results from 6,425 closed or
completed trials.
Whilst the PDQ database only lists NCI approved trials,
there is also a demand for a more comprehensive register of
all trials being conducted in cancer. In the UK, the United
Kingdom Coordinating Committee on Cancer Research
(UKCCCR) is currently compiling a register of UK cancer
trials, and this will be made available for querying over
EuroCODE; France and The Netherlands have already indi-
cated that they will be producing similar registers. Also, the
European Action Against Cancer has funded a project for an
exhaustive listing of all ongoing phase II and phase III trials
in the member states. This will become available in the
course of the next few years.
These databases provide clinical oncologists with an over-
view of the activity of the major cancer cooperative groups.
They also constitute a first attempt at an international regis-
try of on-going clinical trials: the relevance of such a registry
when evaluating the worth of alternative investigational
therapies has been recognised for several years (Dickersin,
1992; Simes, 1986). It is expected that the number of on-line
databases will increase to include all clinical trials in cancer,
whether on-going or closed, from national and regional
groups, and from individual institutions.
The main advantage of these computerised databases over
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the traditional sources of information, such as journals or
periodicals, is that they can be regularly updated and allow
quick and easy access to the latest information. Information
can be selectively retrieved, with only those details which are
relevant being displayed or printed.
On-line randomisation
One of the attractive and original features of EuroCODE is
the on-line registration and randomisation system it provides
for entry of patients into clinical trials. The responsible
clinician merely logs into EuroCODE at any time, day or
night, 7 days a week, and the system checks with the clinician
the patient eligibility for a given protocol. This is done by
asking the investigator a series of questions from the trial
protocol relating to the patient. If all answers are satisfactory
the patient is accepted into the system and, in the case of
randomised trials, the appropriate treatment is assigned. The
patient data including allocated treatment is automatically
added to the study data file and a confirmation sheet is
automatically printed in the clinicians office. Patient entry
through EuroCODE provides the responsible Trials Office
with up to the minute knowledge of patient entry and initi-
ates the other activities associated with patient entry to the
particular protocol, for example, warns the reference
pathologist to expect a specimen.
There are numerous advantages to an on-line registration
system over the more usual telephone call. For example,
spelling mistakes and language difficulties which are com-
monly encountered with telephone registration are greatly
reduced. The system allows a tighter control of eligibility
criteria and prognostic information. These features are parti-
cularly helpful in phase II trials where a lot of 'on-study'
information must be requested and checked before the
patient is entered on the trial. The principal advantage for
phase III trials is the 24 hour service so that patients can be
randomised at any time and without telephoning a Data
Centre. In this way, EuroCODE encourages wide and inter-
national participation in cancer clinical trials. This is parti-
cularly useful as large-scaIe collaborative and international
trials, such as the AXIS trial in colorectal cancer recently
launched by the UKCCCR, become more common. A joint
MRC/EORTC Phase III trial of Cisplatin, Methotrexate and
Vinblastine (CMV) in advanced bladder cancer anticipates
randomisations through EuroCODE from as far afield as
Canada, Finland and Norway.
Exchange ofdata between trial offices
There is currently increasing awareness of the need for col-
laborative efforts between the different Trial Offices, both for
very large trials seeking to detect small treatment im-
provements in common cancers and for more rapid accrual
to medium sized trials in rarer tumours. One of the benefits
of EuroCODE has been that the national trial organisations
can be in closer contact with each other, with exchange of
data between the offices taking place across EuroCODE. It
also facilitates cooperation between EORTC and national
organisations supervising national cancer clinical trials. This
may not be of obvious consequence to the clinician as a user,
but is an example of the way in which the EuroCODE
project has improved communications at all levels.
Electronic mail
An additional benefit of the EuroCODE network is that
oncologists can exchange electronic mail (Email) with other
investigators and with the Trial Offices that coordinate col-
laborative trials. This inexpensive method of communication
can help reduce the administrative burdens of both the Trial
office and the clinicians. It may also guarantee that impor-
tant news about ongoing protocols, for example unexpected
toxicities or treatment adjustments, get communicated to all
investigators simultaneously and accurately.
Thus Email is used for patient data exchange between the
EORTC Data Centre, Brussels and the MRC Cancer Trials
Office, Cambridge; this occurs on a daily basis for col-
laborative trials which are coordinated jointly by the two
data centres, for example the European Osteosarcoma Inter-
group (EOI) trial.
Current situation
There are EuroCODE computer nodes operational at The
Netherlands Cancer Institute, Amsterdam, the MRC Cancer
Trials Office, Cambridge and at the Institut Gustave Roussy,
Villejuif, Paris. These are all linked to the core at the
EORTC Data Centre in Brussels, and thus comprise the
current EuroCODE network. Additional nodes are coming
on line in Germany (Freiburg), Greece (Piraeus), Italy
(Milan) and Spain (Madrid).
The equipment necessary for a clinician to access this
sytem for his own clinic depends upon local circumstances,
but can range from a simple terminal or a microcomputer
connected to a modem on a dial-up line, to any large main-
frame computer provided it is equipped with suitable net-
working facilities. The EuroCODE nodes provide links to
national networks; in the UK, for example, any clinician with
access to the academic network 'JANET' will find connection
to EuroCODE particularly simple, and similar connections
exist to the other national nodes. Advice about the purchase
and setting up of a modem can be provided by the
EuroCODE Steering Group. Once the necessary communica-
tion equipment is in place, operating the system demands no
more than typing on a standard keyboard. If a national node
is available establishing the EuroCODE link can be made by
telephone line, incurrring only the usual charges. If interna-
tional telecommunication links are required the charges are
extremely low compared to equivalent long-distance tele-
phone calls. Once the link is established it is transparent to
the user which particular node, Amsterdam, Brussels, Cam-
bridge or Paris, is being accessed. Any international
exchanges of information between nodes, that are required
for a user query, are done automatically. Apart from the
telecommunication costs access to EuroCODE is free of
charge.
Future developments
Future developments will allow Cancer Trial Offices to
exchange data through the network with appropriate con-
siderations of security. It is anticipated that investigators will
also be able to enter all their patient data directly on-line if
they choose. This will void the need for patient data forms to
be sent through the post. In order to maintain security, the
investigator will not have access to the trial data once
entered. The Trial Office will still oversee the data quality by
appropriate checking facilities as described, for example, by
the COMPACT Steering Committee (1990). This develop-
ment of on-line entry could considerably improve the quality,
completeness and timeliness of the computer file of trial data.
This is particularly useful and important for any interim
analysis to be presented to a Data Monitoring Committee
which oversees the trial results as they are emerging.
The above development will have several longer term im-
plications. It will be possible to provide translation of the
data sheets into other languages, in order to facilitate on-line
data entry to multinational trials. Email facilities, possibly
augmented by computer driven FAX cards, will be able to
provide a convenient method for sending automatic requests
for missing or overdue data to hospitals.
The updated list of cancer protocols maintained by the
UKCCCR is in the process of being made available as an
on-line document accessed through EuroCODE. The British
Association of Cancer United Patients (BACUP) is one
group which has already expressed interest in linking to
EuroCODE in order to access the register. In this way they
would keep abreast of the current developments in cancerTHE EUROCODE PROJECT 609
patient management and care and be able to respond to
patients' requirements for information on clinical trials in
cancer. This would clearly be an important development in
terms of encouraging patient entry.
The UKCCCR is grateful to Digital Equipment Co. Limited, for the
generous donation of a MicroVAXII to provide the UK node for
EuroCODE.
References
COMPACT STEERING COMMITTEE (1991). Improving the quality of
data in clinical trials in cancer. Br. J. Cancer, 63, 412-415.
DICKERSIN, K. (1992). Why register clinical trials? - Revisited.
Contr. Clin. Trials, 13, 170-177.
EUROCODE STEERING COMMITTEE (1990). EuroCODE: a new
approach to collaborative research in clinical oncology. Eur. J.
Cancer & Clin. Oncol., 25, 1905-1906.
FREEDMAN, L.S. (1989). The size of clinical trials in cancer research
- what are the current needs? Br. J. Cancer, 59, 396-400.
GOVERNMENT ACCOUNTING OFFICE (1988). Cancer Treatment
1975-1985: The use of breakthrough treatments for seven types
of cancer. GAO/PEMD-88-12BR, Washington DC.
HUBBARD, S.M., HENNEY, J.E. & DE VITA, V.T. (1987). A computer
data base for information on cancer treatment. New Engl. J.
Med., 316, 315-318.
MOLLER-JENSEN, O., ESTEVE, J., MOLLER, H. & RENARD, H.
(1990). Cancer in the European Community and its member
states. Eur. J. Cancer, 26, 1167-1256.
SIMES, R.J. (1986). Publication bias: the case for an international
registry of clinical trials. J. Clin. Oncol., 4, 1529-1541.